FDA Keeps Brand-Name Drugs on a Fast Path to Market ― Despite Manufacturing Concerns

More disturbing, even when FDA inspectors flagged the potential danger and raised red flags internally, those problems were resolved with the agency in secret ― without a follow-up inspection ― and the drugs were approved for sale. https://t.co/T9MTIsyJs4

— The Daily Beast (@thedailybeast) November 3, 2019